2022
Maternal Diabetes in Youth-Onset Type 2 Diabetes Is Associated With Progressive Dysglycemia and Risk of Complications
Shah R, Chernausek S, ghormli L, Geffner M, Keady J, Kelsey M, Farrell R, Tesfaldet B, Tryggestad J, Van Name M, Isganaitis E. Maternal Diabetes in Youth-Onset Type 2 Diabetes Is Associated With Progressive Dysglycemia and Risk of Complications. The Journal Of Clinical Endocrinology & Metabolism 2022, 108: 1120-1131. PMID: 36446741, PMCID: PMC10306086, DOI: 10.1210/clinem/dgac663.Peer-Reviewed Original ResearchConceptsYouth-onset type 2 diabetesType 2 diabetesMaternal diabetesHeart rate variabilityGlomerular hyperfiltrationParental diabetesGlycemic controlRate variabilityFuture cardiometabolic diseaseParental diabetes historyYouth-onset T2D.Lower heart rate variabilityRisk of complicationsWorse glycemic controlΒ-cell functionRace/ethnicityDiabetes historyCardiometabolic diseasesDiabetes outcomesPrenatal exposureUS cohortGlycemic outcomesRisk factorsDisease progressionUS CentersSafety and Glycemic Outcomes With a Tubeless Automated Insulin Delivery System in Very Young Children With Type 1 Diabetes: A Single-Arm Multicenter Clinical Trial
Sherr JL, Bode BW, Forlenza GP, Laffel LM, Schoelwer MJ, Buckingham BA, Criego AB, DeSalvo DJ, MacLeish SA, Hansen DW, Ly TT, Sherr J, Weyman K, Tichy E, VanName M, Brei M, Zgorski M, Steffen A, Carria L, Bode B, Busby A, Forlenza G, Wadwa R, Slover R, Cobry E, Messer L, Laffel L, Isganaitis E, Ambler-Osborn L, Freiner E, Turcotte C, Volkening L, Schoelwer M, Brown S, Krauthause K, Emory E, Oliveri M, Buckingham B, Ekhlaspour L, Kingman R, Criego A, Schwartz B, Gandrud L, Grieme A, Hyatt J, DeSalvo D, McKay S, DeLaO K, Villegas C, MacLeish S, Wood J, Kaminski B, Casey T, Campbell W, Behm K, Adams R, Hansen D, Stone S, Bzdick S, Bulger J, Agostini L, Doolittle S, Kivilaid K, Kleve K, Ly T, Dumais B, Vienneau T, Huyett L, Lee J, O’Connor J, Benjamin E. Safety and Glycemic Outcomes With a Tubeless Automated Insulin Delivery System in Very Young Children With Type 1 Diabetes: A Single-Arm Multicenter Clinical Trial. Diabetes Care 2022, 45: 1907-1910. PMID: 35678724, PMCID: PMC9346983, DOI: 10.2337/dc21-2359.Peer-Reviewed Original ResearchConceptsInsulin delivery systemsSingle-arm studyLong-term complicationsMulticenter clinical trialType 1 diabetesSensor glucose levelsYoung childrenBaseline data collectionReduced hypoglycemiaDiabetic ketoacidosisGlycemic targetsUsual therapyGlycemic measuresSevere hypoglycemiaDelivery systemStudy endGlycemic outcomesClinical trialsGlucose levelsType 1HypoglycemiaInvestigational systemDlChildrenStudy phaseLong-term Continuous Glucose Monitor Use in Very Young Children With Type 1 Diabetes: One-Year Results From the SENCE Study
Van Name MA, Kanapka LG, DiMeglio LA, Miller KM, Albanese-O’Neill A, Commissariat P, Corathers SD, Harrington KR, Hilliard ME, Anderson BJ, Kelley JC, Laffel LM, MacLeish SA, Nathan BM, Tamborlane WV, Wadwa RP, Willi SM, Williams KM, Wintergerst KA, Woerner S, Wong JC, DeSalvo DJ. Long-term Continuous Glucose Monitor Use in Very Young Children With Type 1 Diabetes: One-Year Results From the SENCE Study. Journal Of Diabetes Science And Technology 2022, 17: 976-987. PMID: 35343269, PMCID: PMC10348002, DOI: 10.1177/19322968221084667.Peer-Reviewed Original ResearchConceptsFamily behavioral interventionsContinuous glucose monitoringBlood glucose monitoringCGM useYoung childrenGlucose monitoringOne-year resultsType 1 diabetesContinuous glucose monitor useHemoglobin A1cCGM groupGlycemic outcomesType 1Behavioral interventionsExtension phaseBGM groupMonitor useOne-year studyCGM technologyDiabetes technologyGlycemiaHypoglycemiaChildrenBehavioural supportGroup
2020
A Randomized Clinical Trial Assessing Continuous Glucose Monitoring (CGM) Use With Standardized Education With or Without a Family Behavioral Intervention Compared With Fingerstick Blood Glucose Monitoring in Very Young Children With Type 1 Diabetes.
Laffel L, Harrington K, Hanono A, Naik N, Ambler-Osborn L, Schultz A, DiMeglio L, Woerne S, Jolivette H, Ismail H, Tebbe M, Newman A, Legge M, Tamborlane W, Van Name M, Weyman K, Finnegan J, Steffen A, Zgorski M, DeSalvo D, Hilliard M, DeLaO K, Xie C, Levy W, Wadwa R, Forlenza G, Majidi S, Alonso G, Weber I, Clay M, Simmons E, Nathan B, Sunni M, Sweet J, Pappenfus B, Kogler A, Ludwig M, Nelson B, Street A, Weingartner D, Albanese-O’Neill A, Haller M, Adams J, Cintron M, Thomas N, Kelley J, Simmons J, William G, Brendle F, Goland R, Williams K, Gandica R, Pollak S, Casciano E, Robinson E, Willi S, Minnock P, Olivos D, Carchidi C, Grant B, Wong J, Adi S, Corathers S, Sheanon N, Fox C, Weis T, MacLeish S, Wood J, Casey T, Campbell W, McGuigan P, Wintergerst K, Watson S, Kingery S, Pierce G, Ruch H, Rayborn L, Rodriguez-Luna M, Deuser A. A Randomized Clinical Trial Assessing Continuous Glucose Monitoring (CGM) Use With Standardized Education With or Without a Family Behavioral Intervention Compared With Fingerstick Blood Glucose Monitoring in Very Young Children With Type 1 Diabetes. Diabetes Care 2020, 44: 464-472. PMID: 33334807, PMCID: PMC9162100, DOI: 10.2337/dc20-1060.Peer-Reviewed Original ResearchConceptsType 1 diabetesBlood glucose monitoringContinuous glucose monitoringFamily behavioral interventionsGlucose monitoringFingerstick blood glucose monitoringBehavioral interventionsSevere hypoglycemic eventsDays/weekYears of ageFear of hypoglycemiaYoung childrenTreatment group comparisonsChildren ages 2Very Young ChildrenHypoglycemic eventsCGM groupDiabetes burdenClinical trialsGlycemic outcomesGlucose levelsPrimary analysisDiabetesBGM groupPercent time
2019
Impact of Switching Youth With Diabetes to Insulin Degludec in Clinical Practice
Elahi S, Patel AD, Guandalini C, Steffen A, Sherr J, Tamborlane WV, Van Name MA. Impact of Switching Youth With Diabetes to Insulin Degludec in Clinical Practice. Endocrine Practice 2019, 25: 226-229. PMID: 30913005, DOI: 10.4158/ep-2018-0417.Peer-Reviewed Original ResearchConceptsType 1 diabetesInsulin degludecDiabetic ketoacidosisGlycemic controlCurrent regimenPatient's current regimenRetrospective chart reviewMonths of treatmentBeta-cell functionType 2 diabetesDiabetes-PatientenUltralong durationChart reviewGlycemic targetsBasal insulinHemoglobin A1cGlycemic outcomesMissed dosesOutcome differencesIDegClinical practiceDiabetes struggleDiabetesType 2Degludec